CALC
NASDAQCalciMedica Inc.
Price$1.00+0.34 (+52.67%)
2026-03-052026-06-08
News · 26 weeks21-100%
2025-12-142026-06-07
Mix1290d
- Insider6(50%)
- SEC Filings5(42%)
- Other1(8%)
Latest news
25 items- SECSEC Form 10-Q filed by CalciMedica Inc.10-Q - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesFDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027LA JOLLA, Calif., May 12, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results for the first quarter ended March
- SECAmendment: SEC Form 10-K/A filed by CalciMedica Inc.10-K/A - CalciMedica, Inc. (0001534133) (Filer)
- INSIDERSEC Form 4 filed by Bardin Stephen4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Leheny A. Rachel4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Hebbar Sudarshan4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Stauderman Kenneth A.4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Dunn Michael J.4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Roberts Eric W4 - CalciMedica, Inc. (0001534133) (Issuer)
- SECSEC Form 8-K filed by CalciMedica Inc.8-K - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form EFFECT filed by CalciMedica Inc.EFFECT - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form S-3 filed by CalciMedica Inc.S-3 - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form 10-K filed by CalciMedica Inc.10-K - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Reports 2025 Financial Results and Provides Clinical UpdatesInternal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 LA JOLLA, Calif., March 3, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CalciMedica Inc.SCHEDULE 13G/A - CalciMedica, Inc. (0001534133) (Subject)
- ANALYSTCalciMedica downgraded by H.C. WainwrightH.C. Wainwright downgraded CalciMedica from Buy to Neutral
- SECSEC Form 8-K filed by CalciMedica Inc.8-K - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee RecommendationSafety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), a population char
- SECSEC Form 10-Q filed by CalciMedica Inc.10-Q - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesEnrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreatitis (AP); final trial design expected in 1H 2026 Cash position expected to fund operations into 2H 2026 LA JOLLA, Calif., Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2025
- PRCalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial HypertensionPreclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with existing treatments Cardiac benefit supports the mechanistic rationale for CRAC channel inhibition in acute kidney injury (AKI), being evaluated in the Phase 2 KOURAGE trial with data expected in 1H 2026 LA JOLLA, Calif., Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immun
CALC FAQ
6 questionsWhere does CALC stock trade?
CalciMedica Inc. (CALC) is listed on NASDAQ.What sector and industry is CALC in?
CalciMedica Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CalciMedica Inc. go public?
CalciMedica Inc. (CALC) completed its IPO in 2023.What are analysts saying about CALC?
CalciMedica Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Neutral on 2026-01-29.What companies are similar to CALC?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CALC side-by-side with any of them on Quantisnow.How can I track CALC on Quantisnow?
Quantisnow aggregates CalciMedica Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CALC to receive live email and push alerts on every new disclosure.